Crystalline forms of Ponatinib hydrochloride

Patent metadata

Field	Value
Publication number	US-11072620-B2
Application number	US-201816621183-A
Country	US
Kind code	B2
Filing date	Jun 15, 2018
Priority date	Jun 20, 2017
Publication date	Jul 27, 2021
Grant date	Jul 27, 2021

Abstract

The present invention provides novel crystalline forms of Ponatinib hydrochloride. Specific crystalline forms provided by the present invention include Ponatinib hydrochloride Form APO-I, APO-III and APO-IV, each of which is obtained from acetonitrile/formic acid solutions. Additionally, Form APO-V is provided, which is obtained from concentrated hydrochloric acid.

First claim

What is claimed is:

1. A crystalline form of Ponatinib hydrochloride, characterized by a powder X-ray diffraction (PXRD) diffractogram comprising peaks, expressed in degrees 2θ (±) 0.2°, at 7.7°, 9.2°, 11.2° and 17.5°.

2. The crystalline form of claim 1 , characterized by a PXRD diffractogram further comprising at least two peaks, expressed in degrees 2θ (±0.2°), selected from the group consisting of 13.5°, 14.4°, 14.9°, 16.5°, 17.5° and 22.9°.

3. The crystalline form of claim 1 , characterized by a PXRD diffractogram further comprising peaks, expressed in degrees 2θ (±0.2°), at 13.5°, 14.4°, 14.9°, 16.5°, 17.5° and 22.9°.

4. The crystalline form of claim 2 , having a weight percentage of water of between approximately 2.7 wt % and 4.1 wt %.

5. The crystalline form of claim 1 , providing a PXRD diffractogram comprising peaks in substantially the same positions (approximately ±0.2° 2θ) as those shown in FIG. 3 .

6. A crystalline form of Ponatinib hydrochloride, characterized by a powder X-ray diffraction (PXRD) diffractogram comprising peaks, expressed in degrees 2θ (±0.2°), at 8.8°, 9.6° and 13.2°.

7. The crystalline form of claim 6 , characterized by a PXRD diffractogram further comprising peaks, expressed in degrees 2θ (±0.2°), at 14.4° and 23.0°.

8. The crystalline form of claim 6 , characterized by a PXRD diffractogram further comprising peaks, expressed in degrees 2θ (±0.2°), at 14.4°, 16.5°, 18.7°, 19.2° and 23.0°.

9. The crystalline form of claim 6 , having a weight percentage of formic acid of at least approximately 3.9 wt %.

10. The crystalline form of claim 6 , having a weight percentage of formic acid of between approximately 3.9 wt % and approximately 7.5 wt %.

11. The crystalline form of claim 6 , having a molar ratio of Ponatinib hydrochloride to formic acid of between approximately 1:0.5 and approximately 1:1.

12. The crystalline form of claim 6 , providing a PXRD diffractogram comprising peaks in substantially the same positions (approximately ±0.2° 2θ) as those shown in FIG. 1 .

13. A pharmaceutical composition comprising the crystalline form of Ponatinib hydrochloride of claim 1 , and one or more pharmaceutically acceptable excipients.

14. The crystalline form of claim 3 , having a weight percentage of water of between approximately 2.7 wt % and 4.1 wt %.

15. The crystalline form of claim 2 , providing a PXRD diffractogram comprising peaks in substantially the same positions (approximately ±0.2° 2θ) as those shown in FIG. 3 .

16. The crystalline form of claim 3 , providing a PXRD diffractogram comprising peaks in substantially the same positions (approximately ±0.2° 2θ) as those shown in FIG. 3 .

Assignees

• Apotex Inc

Inventors

• Souza Fabio E S
• Khalili Bahareh
• Rantanen Katherine A
• Gerster Jenny L
• Bhattacharyya Annyt
• Gorin Boris
• Rey Allan W

Classifications

• C07D487/04 Primary

  Ortho-condensed systems · CPC title

• C07B2200/13

  Crystalline forms, e.g. polymorphs · CPC title

• A61P35/02 Primary

  specific for leukemia · CPC title